TMEFF2 and prostate carcinoma: Administration of 111In-DOTA-anti-TENB2-MMAE antibody was assessed in isolation or following predosing of the anti-TENB2 mAb at doses of 1 mg/kg, 3 mg/kg and 10 mg/kg in LuCaP 77 prostate cancer model.